About Eukaryotic translation initiation factor 3 subunit I
Eukaryotic translation initiation factor 3 subunit I (EIF3I) is a protein
from Homo sapiens identified by UniProt accession
Q13347, 325 residues long.
MolForge cross-references it against 0 known binders and
30 disease associations.
Target properties
| Protein name | Eukaryotic translation initiation factor 3 subunit I |
|---|
| UniProt accession | Q13347 |
|---|
| Gene | EIF3I |
|---|
| Organism | Homo sapiens |
|---|
| Length | 325 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (30)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.16
- neoplasm · score 0.09
- laryngotracheoesophageal cleft · score 0.07
- cancer · score 0.05
- glioblastoma multiforme · score 0.05
- hepatocellular carcinoma · score 0.03
- infection · score 0.02
- infect · score 0.02
- systemic juvenile idiopathic arthritis · score 0.01
- melanoma · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q13347-F1 | alphafold | PREDICTED | 91.93 | — |
Amino-acid sequence (325 residues)
MKPILLQGHE RSITQIKYNR EGDLLFTVAK DPIVNVWYSV NGERLGTYMG HTGAVWCVDA DWDTKHVLTG SADNSCRLWD CETGKQLALL KTNSAVRTCG FDFGGNIIMF STDKQMGYQC FVSFFDLRDP SQIDNNEPYM KIPCNDSKIT SAVWGPLGEC IIAGHESGEL NQYSAKSGEV LVNVKEHSRQ INDIQLSRDM TMFVTASKDN TAKLFDSTTL EHQKTFRTER PVNSAALSPN YDHVVLGGGQ EAMDVTTTST RIGKFEARFF HLAFEEEFGR VKGHFGPINS VAFHPDGKSY SSGGEDGYVR IHYFDPQYFE FEFEA
Explore Eukaryotic translation initiation factor 3 subunit I with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets